GLP-1 & Incretin Science

Six Trials Out of Forty-Two

UKPWritten and published by UK Peptides5 min readUpdated 8 cited sources

The short answer

Ciudin and colleagues published a Bayesian network meta-analysis in Advances in Therapy in 2026 comparing tirzepatide, semaglutide 2.4 mg and liraglutide 3 mg indirectly. Six of 42 identified randomised trials entered the network after a heterogeneity assessment. The study was sponsored by Eli Lilly.

Key facts

Publication
Adv Ther 2026;43(5):2090-2105 (PMID 41820778)
Method
Systematic literature review plus Bayesian network meta-analysis
Trials identified
42
Trials included
6
Included trials
SURMOUNT-1, STEP 1, STEP 5, STEP 8, O'Neil 2018, SCALE Obesity and Prediabetes
Population
Adults without type 2 diabetes, BMI 30+ or 27+ with one complication
Tirzepatide 15 mg vs semaglutide
-6.26% weight (efficacy estimand)
Tirzepatide 15 mg vs liraglutide
-13.95% weight (efficacy estimand)
Sponsor
Eli Lilly

What the analysis set out to do

No trial has randomised all three of tirzepatide, semaglutide and liraglutide against each other, and until recently no trial had randomised tirzepatide against either. A network meta-analysis fills that gap by linking trials through shared comparators: if trial A compares drug 1 with placebo and trial B compares drug 2 with placebo, the two drugs can be compared indirectly through their common placebo arms. This analysis did that for semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide at 5, 10 and 15 mg, in adults without type 2 diabetes with obesity or with overweight plus at least one obesity-related complication.

Six of forty-two, and why that is not automatically a criticism

The systematic review identified 42 randomised controlled trials. Six entered the network: SURMOUNT-1, STEP 1, STEP 5, STEP 8, the O'Neil 2018 dose-ranging trial, and SCALE Obesity and Prediabetes. Excluding 86% of the identified evidence sounds damning and is not, necessarily. An indirect comparison is only valid if the trials being linked are exchangeable: similar populations, similar background therapy, similar outcome definitions. Trials that differ on those dimensions do not add information; they add bias. Discarding them is the correct move. But it is also a decision that determines the answer, made by the analysts, and it is the first thing to interrogate in any network meta-analysis. The paper reports its inclusion reasoning explicitly, which is what allows the interrogation to happen.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What it found

On the efficacy estimand, all three tirzepatide doses produced statistically greater weight reduction than liraglutide, and tirzepatide 10 mg and 15 mg produced statistically greater reduction than semaglutide. Against liraglutide, percentage weight reduction was -12.86% for tirzepatide 10 mg and -13.95% for 15 mg. Against semaglutide 2.4 mg, the corresponding figures were -4.85% and -6.26%. Waist circumference moved in the same direction: -11.79 cm and -12.30 cm against liraglutide, -4.81 cm and -5.32 cm against semaglutide. Safety profiles were reported as generally comparable across all three. Tirzepatide 5 mg was broadly comparable with semaglutide rather than superior to it, which is a detail that tends to disappear in summaries.

The part that makes this analysis unusually interesting

SURMOUNT-5, the open-label head-to-head trial of tirzepatide against semaglutide, was published after this analysis was conducted. The authors say so, and state their reason for not adding it: the maximum-tolerated-dose design meant the response could not be attributed to a specific dose, so it was not translatable to the fixed-dose structure of their network. That makes the comparison that follows independent. SURMOUNT-5 randomised 751 adults for 72 weeks and reported -20.2% with tirzepatide against -13.7% with semaglutide, a difference of 6.5 percentage points. The network meta-analysis, using no head-to-head data at all, estimated -6.26% for tirzepatide 15 mg against semaglutide 2.4 mg. The indirect estimate and the direct trial agree to within a quarter of a percentage point.

Why that agreement matters, and how far to push it

Indirect comparison is routinely dismissed as a weaker substitute for a real trial, and in the hierarchy of evidence it is. But this is a documented case in which an indirect estimate predicted a subsequent head-to-head result almost exactly, in a field where nobody had run the head-to-head yet. That is worth knowing when a health technology assessment rests on indirect evidence, which many do. The caveats are real and should travel with the claim: SURMOUNT-5 used a mix of 10 mg and 15 mg tirzepatide against a mix of 1.7 mg and 2.4 mg semaglutide, so it is not a clean 15 mg versus 2.4 mg comparison; it was open-label where the network's trials were mostly double-blind; and one agreement does not establish that indirect comparison is generally reliable. It establishes that it was reliable here.

Who paid for it, and why that is stated rather than implied

The study was sponsored by Eli Lilly, which markets tirzepatide, and Lilly also funded the journal's rapid service and open access fees. Five of the nine authors are declared employees and shareholders of Eli Lilly. Three are employees of Costello Medical, which was paid by Lilly for analytical services for this study. The remaining author declares honoraria from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk. All of that is stated in the paper's own declarations, in full. The correct response is not to discard the analysis (a sponsored study is not a false one, and the SURMOUNT-5 agreement is evidence that this one estimated well) but to hold the funding in mind against the choices only the analysts could make, of which the exclusion of 36 trials is the largest.

Quick reference

Trial in the networkYearDrug studiedSample size in Table 1
SCALE Obesity and Prediabetes2015Liraglutide 3 mg4,974
O'Neil dose-ranging2018Semaglutide vs liraglutide239
STEP 12021Semaglutide 2.4 mg1,961
STEP 52022Semaglutide 2.4 mg304
STEP 82022Semaglutide vs liraglutide338
SURMOUNT-12022Tirzepatide 5/10/15 mg2,539

Frequently asked questions

Does this replace a head-to-head trial?

No, and the paper does not claim it does. An indirect estimate carries assumptions that a randomised comparison does not need. Its value is that it exists where a head-to-head does not. For tirzepatide against liraglutide, that remains the case.

Should a sponsored meta-analysis be trusted?

It should be read with its sponsorship known, which the disclosure makes possible. Sponsorship is associated on average with results favourable to the sponsor, and that association is a reason for scrutiny rather than a verdict on any single paper. Here the scrutiny is available: the inclusion criteria are stated, the six trials are named, and the central estimate was subsequently matched by an independent trial.

Why exclude 36 trials?

Because a network meta-analysis is only valid if the linked trials are comparable enough that their placebo arms can stand in for each other. Trials in different populations, with different background therapy or different outcome definitions, break that assumption. The exclusions are defensible in principle; whether each one was correct requires reading the supplementary material.

Is tirzepatide therefore better than semaglutide?

On weight reduction at the doses studied, both this analysis and SURMOUNT-5 point the same way, and that is now reasonably well supported. Both are licensed medicines that we do not supply, nothing sold on this site is an alternative to either, and 'better on average weight change' is not the same as 'better for a given person', which depends on tolerability, comorbidity and access.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.